eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
3/2020
vol. 36
 
Share:
Share:
abstract:
Review paper

High dose aripiprazole – clinical use

Andrzej Juryk
1
,
Dominika Dudek
1

  1. Jagiellonian University Medical College, Department of Psychiatry
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (3), 177–185
Online publish date: 2021/12/06
View full text Get citation
 
Aripiprazole is a second-generation antipsychotic medi cation, with a dual mechanism of antagonist and agonist on the receptors D2. Despite the fact that it has been pres ent on the Polish market for over a dozen years, and for several years in the form of the long-acting injections, for many doctors, it is not the drug of the first choice in the first episode of psychosis or mania, especially with accompanying psychomotor agitation. It also has an un just opinion that it can exacerbate psychotic symptoms or increase agitation and the risk of aggression. However, it is more often used as a second-line drug in the presence of metabolic disorders or hyperprolactinaemia, as well as in the case of persistent negative symptoms. Multiple studies and meta-analyses suggest no benefit from aripi prazole doses above 20 mg/day, but registered dosages are as high as 30 mg/day. This article aims to provide an overview of the available data and clinical cases with higher doses, i.e. above 15 aripiprazole per day, which may be useful in the treatment of manic episodes and some cases of schizophrenia, among others.
keywords:

bipolar disorder, schizophrenia, pharmacotherapy, aripiprazole


Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.